title: Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
abstract: Expanded options for treatments directed against pathogens that can be used for bioterrorism are urgently needed. Treatment regimens directed against such pathogens can be identified only by using data derived from in vitro and animal studies. It is crucial that these studies reliably predict the efficacy of proposed treatments in humans. The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for Bacillus anthracis infections and postexposure prophylaxis. An in vitro hollow-fiber infection model that replicates the pharmacokinetic profile of levofloxacin observed in humans (half-life [t(1/2)], 7.5 h) or in animals, such as the mouse or the rhesus monkey (t(1/2), approximately 2 h), was used to evaluate a proposed indication for levofloxacin (500 mg once daily) for the treatment of Bacillus anthracis infections. The results obtained with the in vitro model served as the basis for the doses and the dose schedules that were evaluated in the mouse inhalational anthrax model. The effects of levofloxacin and ciprofloxacin treatment were compared to those of no treatment (untreated controls). The main outcome measure in the in vitro hollow-fiber infection model was a persistent reduction of culture density (> or = 4 log10 reduction) and prevention of the emergence of levofloxacin-resistant organisms. In the mouse inhalational anthrax model the main outcome measure was survival. The results indicated that levofloxacin given once daily with simulated human pharmacokinetics effectively sterilized Bacillus anthracis cultures. By using a simulated animal pharmacokinetic profile, a once-daily dosing regimen that provided a human-equivalent exposure failed to sterilize the cultures. Dosing regimens that "partially humanized" levofloxacin exposures within the constraints of animal pharmacokinetics reproduced the antimicrobial efficacy seen with human pharmacokinetics. In a mouse inhalational anthrax model, once-daily dosing was significantly inferior (survival end point) to regimens of dosing every 12 h or every 6 h with identical total daily levofloxacin doses. These results demonstrate the predictive value of the in vitro hollow-fiber infection model with respect to the success or the failure of treatment regimens in animals. Furthermore, the model permits the evaluation of treatment regimens that "humanize" antibiotic exposures in animal models, enhancing the confidence with which animal models may be used to reliably predict the efficacies of proposed antibiotic treatments in humans in situations (e.g., the release of pathogens as agents of bioterrorism or emerging infectious diseases) where human trials cannot be performed. A treatment regimen effective in rhesus monkeys was identified.
authors.affiliation: Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208, USA.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Deziel
authors.forename: Henry
authors.initials: H
authors.lastname: Heine
authors.forename: Arnold
authors.initials: A
authors.lastname: Louie
authors.forename: Mark
authors.initials: M
authors.lastname: Kao
authors.forename: William R
authors.initials: WR
authors.lastname: Byrne
authors.forename: Jennifer
authors.initials: J
authors.lastname: Basset
authors.forename: Lynda
authors.initials: L
authors.lastname: Miller
authors.forename: Karen
authors.initials: K
authors.lastname: Bush
authors.forename: Michael
authors.initials: M
authors.lastname: Kelly
authors.forename: G L
authors.initials: GL
authors.lastname: Drusano
mesh_terms: D000818:Animals; D000881:Anthrax / Q000188:drug therapy / Q000517:prevention & control*; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001408:Bacillus anthracis / Q000187:drug effects*; D006801:Humans; D064704:Levofloxacin; D008253:Macaca mulatta; D051379:Mice; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D011315:Preventive Medicine
chemical_list: D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin